Interleukin 1 protects against 1-beta-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 2040008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alopecia is one of the most psychologically distressing side effects of cancer chemotherapy. Previously, we made the following observations: (a) treatment of 8-day-old rats with 1-beta-D-arabinofuranosylcytosine (ara-C), doxorubicin, and cyclophosphamide (CYC) consistently produced either total body alopecia (ara-C and CYC) or alopecia confined to the head and proximal part of the neck (doxorubicin); (b) Imuvert, a biological response modifier derived from the bacterium Serratia marcescens, uniformly produced complete protection against alopecia induced by ara-C and doxorubicin but not that induced by CYC; and (c) the protective effect of Imuvert against chemotherapy-induced alopecia is mediated by a monocyte-mediated cytokine. In the experiments reported here, interleukin 1 was examined as the potential cytokine. Interleukin 1 offered excellent protection against alopecia induced by ara-C but not that produced by CYC in the newborn rat animal model.
Medical subject headings
- Alopecia
- Cytarabine
- Interleukin-1